Tuberculosis reactivation in a patient receiving anti-programmed death-1 (PD-1) inhibitor for relapsed Hodgkin's lymphoma

Acta Oncol. 2016;55(4):519-20. doi: 10.3109/0284186X.2015.1125017. Epub 2016 Jan 12.

Authors

Joycelyn J X Lee¹, Alexandre Chan^{2

3}, Tiffany Tang¹

Affiliations

¹ a Division of Medical Oncology , National Cancer Centre Singapore , Singapore.
² b Department of Pharmacy , National Cancer Centre Singapore , Singapore.
³ c Department of Pharmacy , National University of Singapore , Singapore.

PMID: 26754959
DOI: 10.3109/0284186X.2015.1125017

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged, 80 and over
Antibodies, Monoclonal, Humanized / administration & dosage
Antibodies, Monoclonal, Humanized / adverse effects*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Antitubercular Agents / therapeutic use
Hodgkin Disease / drug therapy*
Hodgkin Disease / microbiology
Hodgkin Disease / pathology
Humans
Lymph Nodes / diagnostic imaging
Lymph Nodes / pathology
Male
Molecular Targeted Therapy
Mycobacterium tuberculosis / isolation & purification
Mycobacterium tuberculosis / pathogenicity
Neoplasm Recurrence, Local
Programmed Cell Death 1 Receptor / antagonists & inhibitors*
Tomography, X-Ray Computed
Tuberculosis / chemically induced*
Tuberculosis / drug therapy

Substances

Antibodies, Monoclonal, Humanized
Antitubercular Agents
PDCD1 protein, human
Programmed Cell Death 1 Receptor
pembrolizumab